Physician profile
Marie A Benoit
NPI 1740705730
$2,213.94
in general payments reported to CMS, 2019-2025
13 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.36 · 2022: $719 · 2023: $1,033 · 2024: $125 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $899.87 | 2022-2025 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $263.87 | 2023 | Imbruvica |
| Daiichi Sankyo INC. | $198.13 | 2021-2023 | Injectafer |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $123.34 | 2023 | Reblozyl |
| Incyte Corporation | $110.94 | 2025 | Niktimvo |
| Celgene Corporation | $101.68 | 2022-2023 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $88.63 | 2022-2025 | |
| Janssen Biotech, INC. | $72.88 | 2022-2023 | Darzalex |
| Adaptive Biotechnologies Corporation | $56.10 | 2022 | |
| Karyopharm Therapeutics INC. | $32.51 | 2022 | |
| Astellas Pharma US INC | $16.00 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.